Tokyo Tape
Sign in
← H.U. Group Holdings

Quarterly report · Q3

4544.TEDINET S100SUU5
Period2023-04-01 → 2023-12-31
Filed2024-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 48
MetricValuePeriodScopeSource row
Revenue¥177.5bn2023-04-01 → 2023-12-31Cons.Net sales
Revenue¥260.9bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥201.0bn2022-04-01 → 2022-12-31Cons.Net sales
Operating income−¥1.1bn2023-04-01 → 2023-12-31Cons.Operating income
Operating income¥23.7bn2022-04-01 → 2022-12-31Cons.Operating income
Ordinary income−¥2.9bn2023-04-01 → 2023-12-31Cons.Ordinary income
Ordinary income¥22.0bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥23.2bn2022-04-01 → 2022-12-31Cons.Ordinary income
Profit before tax−¥3.2bn2023-04-01 → 2023-12-31Cons.Income before income taxes
Profit before tax¥25.8bn2022-04-01 → 2022-12-31Cons.Income before income taxes
Net income (owners)−¥3.3bn2023-04-01 → 2023-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥15.7bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥18.8bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income−¥3.3bn2023-04-01 → 2023-12-31Cons.Profit loss
Net income¥18.8bn2022-04-01 → 2022-12-31Cons.Profit loss
Total assets¥284.1bnat 2023-12-31Cons.Assets
Total assets¥297.9bnat 2023-03-31Cons.Assets
Total assets¥281.9bnat 2022-12-31Cons.Total assets (5-year summary)
Total liabilities¥140.9bnat 2023-12-31Cons.Liabilities
Total liabilities¥147.9bnat 2023-03-31Cons.Liabilities
Net assets / equity¥143.2bnat 2023-12-31Cons.Net assets
Net assets / equity¥150.0bnat 2023-03-31Cons.Net assets
Net assets / equity¥153.3bnat 2022-12-31Cons.Net assets (5-year summary)
Cash and deposits¥40.4bnat 2023-12-31Cons.Cash and deposits
Cash and deposits¥44.2bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥40.4bnat 2023-12-31Cons.Cash and cash equivalents
Cash & equivalents¥44.2bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥30.5bnat 2022-12-31Cons.Cash and cash equivalents
Cash & equivalents¥46.5bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow¥9.4bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in operating activities
Operating cash flow¥32.5bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥19.2bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in operating activities
Investing cash flow−¥9.2bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥29.6bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥24.9bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in investment activities
Financing cash flow−¥4.6bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥5.8bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥10.9bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in financing activities
EPS (basic)¥-58.782023-04-01 → 2023-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-26.782023-10-01 → 2023-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥275.522022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥331.222022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥57.352022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥275.52022-04-01 → 2023-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥331.192022-04-01 → 2022-12-31Cons.Diluted earnings per share (5-year summary)
Equity ratio50.4%at 2023-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio50.3%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio54.4%at 2022-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 38
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-12-31−¥4.5bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-12-31−¥4.5bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-12-31−¥4.6bn
jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue2023-04-01 → 2023-12-31¥110.2bn
jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue external2023-04-01 → 2023-12-31¥110.0bn
jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥214m
jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segmentsegment profit2023-04-01 → 2023-12-31−¥8.6bn
jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue2023-04-01 → 2023-12-31¥50.7bn
jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue external2023-04-01 → 2023-12-31¥46.4bn
jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥4.3bn
jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segmentsegment profit2023-04-01 → 2023-12-31¥11.0bn
jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segmentrevenue2023-04-01 → 2023-12-31¥21.1bn
jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segmentrevenue external2023-04-01 → 2023-12-31¥21.1bn
jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥4m
jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segmentsegment profit2023-04-01 → 2023-12-31¥938m
—segment totalrevenue2023-04-01 → 2023-12-31¥182.0bn
—segment totalrevenue external2023-04-01 → 2023-12-31¥177.5bn
—segment totalrevenue intersegment2023-04-01 → 2023-12-31¥4.5bn
—segment totalsegment profit2023-04-01 → 2023-12-31¥3.4bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥6.2bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥6.2bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥3.3bn
jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥124.9bn
jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥124.7bn
jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥212m
jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥2.7bn
jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥61.6bn
jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥55.6bn
jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥5.9bn
jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥23.5bn
jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segmentrevenue2022-04-01 → 2022-12-31¥20.7bn
jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segmentrevenue external2022-04-01 → 2022-12-31¥20.6bn
jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥15m
jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segmentsegment profit2022-04-01 → 2022-12-31¥825m
—segment totalrevenue2022-04-01 → 2022-12-31¥207.1bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥201.0bn
—segment totalrevenue intersegment2022-04-01 → 2022-12-31¥6.2bn
—segment totalsegment profit2022-04-01 → 2022-12-31¥26.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 485
ItemContextValueUnit
Other nclPrior1YearInstant13750000000JPY
Other nclCurrentQuarterInstant13917000000JPY
Noncurrent liabilitiesPrior1YearInstant83506000000JPY
Noncurrent liabilitiesCurrentQuarterInstant83110000000JPY
LiabilitiesPrior1YearInstant147877000000JPY
LiabilitiesCurrentQuarterInstant140905000000JPY
Capital stockPrior1YearInstant9274000000JPY
Capital stockCurrentQuarterInstant9279000000JPY
Capital surplusPrior1YearInstant24996000000JPY
Capital surplusCurrentQuarterInstant25001000000JPY
Retained earningsPrior1YearInstant112422000000JPY
Retained earningsCurrentQuarterInstant101907000000JPY
Treasury stockPrior1YearInstant-2060000000JPY
Treasury stockCurrentQuarterInstant-2256000000JPY
Shareholders equityPrior1YearInstant144633000000JPY
Shareholders equityCurrentQuarterInstant133932000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant118000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant599000000JPY
Foreign currency translation adjustmentPrior1YearInstant7140000000JPY
Foreign currency translation adjustmentCurrentQuarterInstant10350000000JPY
Remeasurements of defined benefit plansPrior1YearInstant-1919000000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant-1794000000JPY
Valuation and translation adjustmentsPrior1YearInstant5339000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant9155000000JPY
Subscription rights to sharesPrior1YearInstant74000000JPY
Subscription rights to sharesCurrentQuarterInstant83000000JPY
Net assetsPrior1YearInstant150047000000JPY
Net assetsCurrentQuarterInstant143171000000JPY
Liabilities and net assetsPrior1YearInstant297924000000JPY
Liabilities and net assetsCurrentQuarterInstant284076000000JPY
Net salesPrior1YTDDuration200963000000JPY
Net salesCurrentYTDDuration177511000000JPY
Cost of salesPrior1YTDDuration127934000000JPY
Cost of salesCurrentYTDDuration128798000000JPY
Gross profitPrior1YTDDuration73028000000JPY
Gross profitCurrentYTDDuration48712000000JPY
Selling general and administrative expensesPrior1YTDDuration49344000000JPY
Selling general and administrative expensesCurrentYTDDuration49860000000JPY
Operating incomePrior1YTDDuration23683000000JPY
Operating incomeCurrentYTDDuration-1147000000JPY
Interest income noiPrior1YTDDuration147000000JPY
Interest income noiCurrentYTDDuration335000000JPY
Dividends income noiPrior1YTDDuration49000000JPY
Dividends income noiCurrentYTDDuration89000000JPY
Foreign exchange gains noiPrior1YTDDuration582000000JPY
Foreign exchange gains noiCurrentYTDDuration406000000JPY
Gain on investments in capital noiPrior1YTDDuration276000000JPY
Gain on investments in capital noiCurrentYTDDuration－JPY
Other noiPrior1YTDDuration243000000JPY
Other noiCurrentYTDDuration251000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-12-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2023-04-01/2023-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass